CN1552734A - 重组腺伴随病毒载体介导的肿瘤坏死因子相关的细胞凋亡配体肽段及其用途 - Google Patents
重组腺伴随病毒载体介导的肿瘤坏死因子相关的细胞凋亡配体肽段及其用途 Download PDFInfo
- Publication number
- CN1552734A CN1552734A CNA031383572A CN03138357A CN1552734A CN 1552734 A CN1552734 A CN 1552734A CN A031383572 A CNA031383572 A CN A031383572A CN 03138357 A CN03138357 A CN 03138357A CN 1552734 A CN1552734 A CN 1552734A
- Authority
- CN
- China
- Prior art keywords
- trail
- aav
- expression vector
- cell
- recombinant expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003446 ligand Substances 0.000 title abstract description 4
- 241000700605 Viruses Species 0.000 title description 28
- 108090000765 processed proteins & peptides Proteins 0.000 title description 4
- 230000006798 recombination Effects 0.000 title 1
- 238000005215 recombination Methods 0.000 title 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 11
- 201000005202 lung cancer Diseases 0.000 claims abstract description 11
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000013604 expression vector Substances 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 210000004881 tumor cell Anatomy 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 12
- 238000003259 recombinant expression Methods 0.000 claims description 12
- 206010027457 Metastases to liver Diseases 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 7
- 210000005229 liver cell Anatomy 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 101150033556 pfd-6 gene Proteins 0.000 claims description 5
- 108020004414 DNA Proteins 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 108010051542 Early Growth Response Protein 1 Proteins 0.000 claims description 2
- 102100023226 Early growth response protein 1 Human genes 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 abstract description 37
- 208000014018 liver neoplasm Diseases 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 abstract 1
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 108700012411 TNFSF10 Proteins 0.000 description 69
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 49
- 230000008521 reorganization Effects 0.000 description 20
- 238000000034 method Methods 0.000 description 14
- 230000006907 apoptotic process Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 7
- 201000007270 liver cancer Diseases 0.000 description 7
- 206010061289 metastatic neoplasm Diseases 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 230000001394 metastastic effect Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 102000018594 Tumour necrosis factor Human genes 0.000 description 4
- 108050007852 Tumour necrosis factor Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000003240 portal vein Anatomy 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101000824887 Bos taurus Somatotropin Proteins 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220023256 rs387907547 Human genes 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- -1 Streptomycin sulphates Chemical class 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 102220369445 c.668T>C Human genes 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002989 hepatic vein Anatomy 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 102220023257 rs387907546 Human genes 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN031383572A CN1552734B (zh) | 2003-05-28 | 2003-05-28 | 重组腺伴随病毒载体介导的肿瘤坏死因子相关的细胞凋亡配体肽段及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN031383572A CN1552734B (zh) | 2003-05-28 | 2003-05-28 | 重组腺伴随病毒载体介导的肿瘤坏死因子相关的细胞凋亡配体肽段及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1552734A true CN1552734A (zh) | 2004-12-08 |
CN1552734B CN1552734B (zh) | 2013-04-24 |
Family
ID=34323709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN031383572A Expired - Lifetime CN1552734B (zh) | 2003-05-28 | 2003-05-28 | 重组腺伴随病毒载体介导的肿瘤坏死因子相关的细胞凋亡配体肽段及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1552734B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1966082B (zh) * | 2006-11-03 | 2010-06-30 | 许瑞安 | 一种防治结直肠癌的基因药物及其制备方法和用途 |
CN102250254A (zh) * | 2010-05-19 | 2011-11-23 | 江苏先声药物研究有限公司 | 肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用 |
CN102329387A (zh) * | 2011-09-23 | 2012-01-25 | 昆明理工大学 | 一种抗病毒蛋白trail114-281及其制备方法 |
CN103288966A (zh) * | 2013-05-17 | 2013-09-11 | 华侨大学 | 一种融合受体及其用于治疗大肠癌的基因药物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6284236B1 (en) * | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
-
2003
- 2003-05-28 CN CN031383572A patent/CN1552734B/zh not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1966082B (zh) * | 2006-11-03 | 2010-06-30 | 许瑞安 | 一种防治结直肠癌的基因药物及其制备方法和用途 |
CN102250254A (zh) * | 2010-05-19 | 2011-11-23 | 江苏先声药物研究有限公司 | 肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用 |
CN102329387A (zh) * | 2011-09-23 | 2012-01-25 | 昆明理工大学 | 一种抗病毒蛋白trail114-281及其制备方法 |
CN103288966A (zh) * | 2013-05-17 | 2013-09-11 | 华侨大学 | 一种融合受体及其用于治疗大肠癌的基因药物 |
CN103288966B (zh) * | 2013-05-17 | 2015-01-21 | 华侨大学 | 一种融合受体及其用于治疗大肠癌的基因药物 |
Also Published As
Publication number | Publication date |
---|---|
CN1552734B (zh) | 2013-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108473527A (zh) | 用于消除免疫抑制疗法期间jc病毒激活和pml(进行性多灶性白质脑病)风险的基因编辑方法和组合物 | |
ES2202452T3 (es) | Proteina de union a quimiocinas y metodos de uso para la misma. | |
CN111635462A (zh) | 一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用 | |
CN1106846C (zh) | 抗癌症剂 | |
CN116917470A (zh) | PAN-RAS mRNA癌症疫苗 | |
CN111205361A (zh) | 白介素21蛋白(il21)突变体及其应用 | |
CN1552734A (zh) | 重组腺伴随病毒载体介导的肿瘤坏死因子相关的细胞凋亡配体肽段及其用途 | |
CN103547280B (zh) | 用于药物组合物的巨噬细胞活化因子 | |
CN1824775A (zh) | 重组人血管抑素k1-3的制备工艺及其制品在肿瘤治疗药物中的应用 | |
CN100341897C (zh) | 肿瘤新生血管特异性结合多肽CRGDC与新型重组人肿瘤坏死因子nrhTNF融合蛋白及制备方法 | |
CN1225285C (zh) | 基因治疗剂 | |
CN109609553B (zh) | 提高nk细胞靶向作用力的方法及ccr5基因的应用 | |
CN1654478A (zh) | 聚乙二醇修饰α-干扰素1b的制备方法 | |
CN101302256A (zh) | 一种新的重组融合分子及其抗肿瘤治疗作用 | |
CN1176099C (zh) | 天然离解素γ基因以及抗肿瘤活性多肽离解素γ | |
CN106366180A (zh) | 一种上皮生长因子受体免疫原多肽及其用途 | |
CN100335499C (zh) | C端氨基酸内酯修饰型胸腺素α1及其应用 | |
CN105420260A (zh) | 重组靶向Wnt融合蛋白及其在制备抗癌药中的应用 | |
CN100430412C (zh) | 核酸分子rtn4bsr6及其在制备抗癌药物中的应用 | |
CN105968211A (zh) | 一种重组抗病毒蛋白及其制备方法和应用 | |
CN1071586A (zh) | 作药物用的突变生长因子受体及其治疗癌的应用 | |
Chen et al. | Preparation of rAAV/hFlX by HSV/AAV hybrid helper virus and evaluation of its safety | |
WO2024097894A1 (en) | Compositions and methods of ribonucleic acid vaccines encoding nye-so-1 | |
CN112143711A (zh) | 重组痘瘤病毒、药物组合物及其构建方法和应用 | |
JP2024522215A (ja) | マルチプレックス化TP53および汎RAS mRNAがんワクチン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 201213 China (Shanghai) free trade Cailun Road Room 406 No. 781 experimentation area Patentee after: OBIO TECHNOLOGY (SHANGHAI) Corp.,Ltd. Address before: 201213, 10F, building 1, Heng International Building, 1238 Zhangjiang Road, Shanghai, Pudong New Area Patentee before: Obio Technology (Shanghai) Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20160427 Address after: 201213, 10F, building 1, Heng International Building, 1238 Zhangjiang Road, Shanghai, Pudong New Area Patentee after: Obio Technology (Shanghai) Co.,Ltd. Address before: 100005 Beijing, Dongdan, No. three, No. 5, No. Patentee before: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences Effective date of registration: 20160427 Address after: 100005 No. three, five Dongdan, Beijing, Dongcheng District Patentee after: INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES Patentee after: THE University OF HONG KONG Address before: 100005 No. three, five Dongdan, Beijing, Dongcheng District Patentee before: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences Patentee before: Molecular Biology Institute The University of Hong Kong Effective date of registration: 20160427 Address after: 100005 Beijing, Dongdan, No. three, No. 5, No. Patentee after: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences Address before: 100005 No. three, five Dongdan, Beijing, Dongcheng District Patentee before: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences Patentee before: VERSITECH Ltd. Effective date of registration: 20160427 Address after: 100005 No. three, five Dongdan, Beijing, Dongcheng District Patentee after: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences Patentee after: VERSITECH Ltd. Address before: 100005 No. three, five Dongdan, Beijing, Dongcheng District Patentee before: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences Patentee before: The University of Hong Kong |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20041208 Assignee: Shanghai Puchuang Longke Finance Leasing Co.,Ltd. Assignor: OBIO TECHNOLOGY (SHANGHAI) Corp.,Ltd. Contract record no.: X2019310000030 Denomination of invention: Recombination glant associated virus carrier induced TNF concerned cytonecrosis ligand peptide segment and its use Granted publication date: 20130424 License type: Exclusive License Record date: 20191226 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Recombination glant associated virus carrier induced TNF concerned cytonecrosis ligand peptide segment and its use Effective date of registration: 20191227 Granted publication date: 20130424 Pledgee: Shanghai Puchuang Longke Finance Leasing Co.,Ltd. Pledgor: OBIO TECHNOLOGY (SHANGHAI) Corp.,Ltd. Registration number: Y2019310000039 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201228 Granted publication date: 20130424 Pledgee: Shanghai Puchuang Longke Finance Leasing Co.,Ltd. Pledgor: OBIO TECHNOLOGY (SHANGHAI) Corp.,Ltd. Registration number: Y2019310000039 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Shanghai Puchuang Longke Finance Leasing Co.,Ltd. Assignor: OBIO TECHNOLOGY (SHANGHAI) Corp.,Ltd. Contract record no.: X2019310000030 Date of cancellation: 20210106 |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 201318 building 19, Lane 908, Ziping Road, international medical park, Pudong New Area, Shanghai Patentee after: OBIO TECHNOLOGY (SHANGHAI) Corp.,Ltd. Address before: Room 406, 781 Cailun Road, China (Shanghai) pilot Free Trade Zone, 201213 Patentee before: OBIO TECHNOLOGY (SHANGHAI) Corp.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20130424 |